TWi Biotechnology’s Postpartum Depression Drug Completes U.S. Phase II Enrollment
 
TWi Biotechnology Inc. (6610) announced that its oral drug candidate NORA520, developed for postpartum depression (PPD), has completed patient enrollment for its U.S. Phase II clinical trial (NCT06285916). A total of 93 participants have been recruited, with top-line results expected in Q4 2025.
 
Key points:
 

• Novel design: NORA520 is a prodrug-based oral formulation, targeting both PPD and Major Depressive Disorder (MDD). 
• Strategic growth: Following the merger with Ducan Pharma (to close Sept. 30, 2025), TWi Biotechnology’s pipeline will expand from rare diseases and dermatology to CNS therapeutics. 
• Future outlook: The company plans to accelerate global licensing and international collaborations to strengthen its portfolio.